Prostate Cancer and Prostatic Diseases

Papers
(The H4-Index of Prostate Cancer and Prostatic Diseases is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging112
Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate?98
Concerns regarding prostate cancer screening guidelines in minority populations93
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction73
New BPH therapy classification: what really FITs?67
Perioperative outcomes of HoLEP, ThuLEP, and TURP in patients with prostate cancer: results from the GRAND study62
Will generalist medical artificial intelligence be the future path for health-related natural language processing models?55
Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis52
Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States50
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer49
Integrating clinical and public health perspectives on statin use and prostate cancer risk: addressing key limitations and future directions43
Focal radiation therapies for localized prostate cancer: a systematic review of clinical evidence and outcomes43
Hypofractionated radiotherapy in elderly patients (≥75 years) affected by localized prostate cancer: a multicenter retrospective analysis from the IPOPROMISE study42
Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs)39
Best of 2022 in prostate cancer and prostatic diseases37
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis36
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or andro35
Sexual outcomes in men who have sex with men who underwent radical prostatectomy35
Concurrent prognostic utility of lymph node count and lymph node density for men with pathological node-positive prostate cancer35
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations35
Stereotactic body radiotherapy: a second chance for radio-recurrent prostate cancer34
Incidence of prostate cancer in transgender women in the US: a large database analysis34
Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients32
Development and validation of a clinical nomogram to predict prostatic inflammation in men with lower urinary tract symptoms32
Feasibility and safety study of the Flostentâ„¢ system (RAPID-I)32
Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study32
Missing the full picture: Pathology, anatomy, and operator effects in HoLEP comparisons32
Prostate cancer and podcasts: an analysis and assessment of the quality of information about prostate cancer available on podcasts31
Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study31
Use of a Schelin catheter for transurethral intraprostatic anesthesia (TUIA) prior to iTIND procedure31
TRexit is going one step further30
Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer30
Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy30
Correction: Application of next-generation imaging in biochemically recurrent prostate cancer30
0.21846199035645